CNS Pharmaceuticals (CNSP) investor relations material

Executive summary

• Announced a strategic transformation in March 2026, appointing a new CEO and executive team, and shifting focus to innovative therapies for serious diseases and acquisition-driven growth in clinical-stage neurology and oncology assets.

• Actively pursuing acquisitions and out-licensing legacy assets TPI 287 and Berubicin.

• Completed an oversubscribed $22.5 million private placement in May 2026 to fund operations and asset acquisitions.

• Multiple executive transitions, including new CEO, CFO, and CMO appointments and severance agreements for outgoing executives.

Financial highlights

• Net loss for Q1 2026 was $4.94 million, up from $4.30 million in Q1 2025, driven by higher R&D and professional expenses.

• Cash and cash equivalents as of March 31, 2026, were $2.95 million, not including the $22.5 million raised in May.

• General and administrative expense rose to $1.43 million for Q1 2026 from $1.10 million in Q1 2025, mainly due to strategic review and leadership changes.

• Research and development expense increased to $3.54 million from $3.24 million year-over-year, driven by higher placement services and headcount.

• Operating cash outflow was $4.65 million in Q1 2026, compared to $3.24 million in Q1 2025.

Outlook and guidance

• Management expects current cash plus May 2026 financing to fund operations beyond 12 months from the financial statement issuance date.

• Focus remains on acquiring differentiated clinical-stage assets with near-term value inflection catalysts.

• Future R&D expenses will depend on timing and nature of new asset acquisitions.

• Additional capital will be required for advancing drug candidates; no commitments for further financing are in place.